Coherus Oncology, Inc.
CHRS
$0.7472
-$0.0204-2.66%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -85.97% | -23.50% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -85.97% | -23.50% | |||
| Cost of Revenue | -92.16% | 63.24% | |||
| Gross Profit | -75.62% | -59.45% | |||
| SG&A Expenses | -24.78% | -0.42% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -40.87% | 16.24% | |||
| Operating Income | -27.82% | -456.54% | |||
| Income Before Tax | 6.51% | -371.55% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 6.51% | -371.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -11.58% | -371.55% | |||
| EBIT | -27.82% | -456.54% | |||
| EBITDA | -28.62% | -613.37% | |||
| EPS Basic | -11.18% | -370.74% | |||
| Normalized Basic EPS | 78.59% | -1,948.89% | |||
| EPS Diluted | -4.20% | -402.25% | |||
| Normalized Diluted EPS | 78.59% | -1,948.89% | |||
| Average Basic Shares Outstanding | 0.38% | 0.18% | |||
| Average Diluted Shares Outstanding | 0.38% | 0.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||